PURCHASE, N.Y.—Nutrition 21, LLC announced the presentation of new clinical study results supporting Nitrosigine inositol-stabilized arginine silicate. The study, “A Clinical Evaluation to Determine the Safety, Pharmacokinetics and Pharmacodynamics of an Inositol-Stabilized Arginine Silicate Dietary Supplement in Healthy Adult Males," was presented at the Experimental Biology 2014 annual meeting’s poster session and will be published in Federation of American Societies for Experimental Biology Journal (FASEB).
The study demonstrated significant increases in plasma arginine levels and serum silicon levels after a single dose of Nitrosigine. A significant increase in nitric oxide levels (measured as salivary nitrites) was also seen after 14 days of consumption. The results of the study support the use of Nitrosigine as a bioavailable source of arginine and silicon, validating preclinical studies and confirming Nitrosigine as an effective ingredients in products for sports nutrition, men’s health and cardiovascular health.
“We are immensely pleased with the new clinical results. The clinical study confirms our pre-clinical work, and supports Nitrosigine’s ability to optimize the benefits of rigorous workouts by significantly increasing nitric oxide levels," said James Komorowski, MS, CNS, vice president, scientific and regulatory affairs at Nutrition 21. “Fitness-focused customers who want to get the most out of their training regimen, will appreciate that Nitrosigine is quickly absorbed by the body, taking effect in 30 minutes and lasting up to three hours. Nitrosigine has also been shown to significantly raise arginine and silicon levels - both important nutrients for cardiovascular performance."